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Abstract 
The myotonic dystrophy-related Cdc42-binding kinases MRCKα and MRCKβ 
contribute to the regulation of actin-myosin cytoskeleton organization and dynamics, 
acting in concert with the Rho-associated coiled-coil kinases ROCK1 and ROCK2. 
The absence of highly potent and selective MRCK inhibitors has resulted in relatively 
little knowledge of the potential roles of these kinases in cancer. Here we report the 
discovery of the azaindole compounds BDP8900 and BDP9066 as potent and 
selective MRCK inhibitors that reduce substrate phosphorylation, leading to 
morphological changes in cancer cells along with inhibition of their motility and 
invasive character. In over 750 human cancer cell lines tested, BDP8900 and 
BDP9066 displayed consistent anti-proliferative effects with greatest activity in 
hematological cancer cells. Mass spectrometry identified MRCKα S1003 as an 
autophosphorylation site, enabling development of a phosphorylation-sensitive 
antibody tool to report on MRCKα status in tumor specimens. In a two-stage 
chemical carcinogenesis model of murine squamous cell carcinoma, topical 
treatments reduced MRCKα S1003 autophosphorylation and skin papilloma 
outgrowth. In parallel work, we validated a phospho-selective antibody with the 
capability to monitor drug pharmacodynamics. Taken together, our findings establish 
an important oncogenic role for MRCK in cancer, and they offer an initial preclinical 
proof of concept for MRCK inhibition as a valid therapeutic strategy.  
 
Significance 
The development of selective small molecule inhibitors of the Cdc42-binding MRCK 
kinases reveal its essential roles in cancer cell viability, migration and invasive 
character. 
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Introduction 
The actin-myosin cytoskeleton provides the structural framework that determines cell 
shape, and also is the source of physical force which directly powers biological 
activities including adhesion, migration and cell division. In addition, numerous 
processes are promoted by the actin-myosin cytoskeleton via less direct routes, such 
as gene transcription and proliferation, which collectively contribute to cancer (1). 
Although unlikely to be a primary cancer driver, accumulating evidence indicates that 
the actin-myosin cytoskeleton provides a critically important ancillary role in tumor 
growth and spread, which makes actin-myosin cytoskeleton regulators potential 
targets for cancer chemotherapy (2). 
 In non-muscle cells, a key event in promoting actin-myosin contractility is the 
phosphorylation of class 2 regulatory myosin light chains (MLC2) on Thr18 and 
Ser19 residues, which activates myosin ATP activity to drive the interaction of 
myosin heavy and light chain complexes with filamentous actin (F-actin) (3). 
Prominent MLC2 phosphorylating enzymes are the ROCK1 and ROCK2 kinases (4), 
which act downstream of the RhoA and RhoC small GTPases to regulate 
cytoskeleton organization and dynamics (5). However, ROCK1 and ROCK2 are not 
the only kinases regulated by Rho family GTPases; the myotonic dystrophy-related 
Cdc42-binding kinases (MRCK) interact with Cdc42 and catalyze phosphorylation of 
a similar set of substrates, including MLC2 (6,7). There are three MRCK kinases; the 
widely-expressed and closely-related MRCKα and MRCKβ, and the more divergent 
MRCKγ which is considerably more restricted in its tissue expression. 
The roles of MRCK signaling in normal cell function and contributions to 
cancer are less well characterized than for ROCK, largely due to two historical 
factors: ROCK kinases were identified before (4) the MRCK kinases (8,9), and 
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because of the discovery in 1997 of the relatively potent and selective small 
molecule ROCK inhibitor Y27632 (10), which has enabled two decades of research 
on ROCK biology. The large body of ROCK knowledge also catalyzed small 
molecule inhibitor discovery efforts, and ROCK inhibitors have been shown to have 
beneficial therapeutic effects in numerous pre-clinical cancer models (11), which has 
contributed to their further development for clinical use. 
One aspect of cancer with which actin-myosin cytoskeleton regulators, 
including ROCK and MRCK, are clearly associated is tumor cell invasion and 
metastasis (12). The metastatic spread of cancer cells is the main cause of cancer 
mortality, believed to contribute up to 90% of all cancer related deaths (13). It has 
become increasingly appreciated that the same proteins that enable distant 
metastasis also contribute to primary tumor growth (14); therefore, drugs that restrict 
processes which contribute to cancer spread (e.g. motility, local invasion) also have 
beneficial effects on reducing tumor growth and progression. 
It has been demonstrated in several contexts that the concerted inhibition of 
ROCK and MRCK kinases has greater effects than blocking either ROCK or MRCK 
alone (15-17). In addition, MRCK knockdown or inhibition alone was sufficient to 
reduce 3D invasion by squamous cell carcinoma (SCC) cells (18,19). These results 
suggest that there are likely to be clinical scenarios in which MRCK inhibitors would 
have therapeutic benefits, either alone or when combined with ROCK inhibition (20). 
However, the absence of potent and highly selective small molecule inhibitors has 
restricted research on MRCK relative to the advances made for other kinases for 
which useful chemical biology tools are readily available. 
To determine how MRCK contributes to biological processes, including 
regulation of cell morphology and motility, and to evaluate MRCK as a cancer drug 
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target, selective and potent MRCK inhibitors were developed, starting from a ligand-
efficient fragment that was identified in a focused fragment library screen using an 
MRCKβ biochemical assay. Structure-guided fragment elaboration led to the novel 
MRCK inhibitors BDP8900 and BDP9066, which are considerably more potent and 
selective than the previously described BDP5290 (19), or the mixed ROCK-MRCK 
inhibitor DJ4 (17) or PKC-MRCK inhibitor chelerythrine (21). Screening of more than 
750 human cancer cell lines, from more than 40 different cancer types, for anti-
proliferative effects of BDP8900 and BDP9066 identified hematological cancers as 
the most sensitive malignancy type. Mass spectrometry led to the discovery and 
validation of MRCKα S1003 autophosphorylation as a pharmacodynamic biomarker 
that enabled evaluation of on-target drug action in tissues, as well as a biomarker of 
MRCKα activity in skin tumors. BDP9066 treatment of SCC cells induced changes in 
cell morphology, motility and invasion, while topical treatment of mice in a two-stage 
chemical carcinogenesis model of SCC significantly reduced papilloma growth and 
MRCKα S1003 autophosphorylation. These results demonstrate that the potent and 
selective inhibitors BDP8900 and BDP9066 are valuable chemical biology tools to 
identify MRCK biological functions and roles in cancer, and that MRCK inhibition has 
in vivo therapeutic effects on skin cancer in mice. 
 
 Methods 
Kinase inhibition assays. 
MRCKα, MRCKβ, ROCK1 and ROCK2 assays were performed as described (19). 
Recombinant kinase proteins (Life Technologies) at 8-12 nM were incubated at room 
temperature for 60 min with 100 nM FAM-S6-ribosomal protein derived peptide (Alta 
Biosciences) with 1 µM ATP and 0.5 mM MgCl2 in 20 mM Tris buffer (pH 7.4) 
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containing 0.01% (v/v) Tween20, 1 mM DTT for MRCKα and β; or 1 M ATP, 10 mM 
MgCl2 in 20 mM Tris buffer (pH 7.5) containing 0.25 mM EGTA, 0.01% (v/v) Triton X-
100, 1 mM DTT for ROCK1 and ROCK2. Reactions were stopped by adding 2 
volumes 0.25% (v/v) IMAP binding reagent in 1X IMAP binding buffer A (Molecular 
Devices). After 30 min to allow binding reagent to bind phosphorylated peptide, 
fluorescence polarization was measured on a Tecan Saphire2 plate reader at 
excitation (470 nm) and emission (530 nm) wavelengths. Inhibition was calculated 
using no inhibitor (0%) or no enzyme (100%) controls. MRCKα and MRCKβ kinases 
assays by out-sourced supplier were carried out in 50 mM HEPES pH 7.5, 0.01% 
(v/v) BRIJ-35, 10 mM MgCl2, 1 mM EGTA and 2 µM Ser/Thr 13 peptide substrate, 
with 1 hour incubation before addition of development reagent and quantification by 
fluorescence resonance energy transfer (FRET). Kinase selectivity profiling was 
performed by Invitrogen with indicated concentrations of BDP8900 or BDP9066. 
 
Cell culture  
MDA MB 231 D3H2LN Luc cells (Caliper LifeScience, obtained 2006), MDA MB 231 
D3H2LN Luc TetOn MRCKβ, ROCK1 and ROCK2 inducible cell lines (19), human 
cancer-associated fibroblasts (obtained 2008) and SCC12 human squamous cell 
carcinoma cells (18) (gift of Erik Sahai, Crick Institute, London UK; obtained 2006) 
were cultured as described (19). SCC12 organotypic invasion assays were 
performed as described (19). 
 CRISPR/Cas9 mediated MRCKα, MRCKβ, and MRCKαβ knockouts in MDA 
MB 231 D3H2LN Luc cells were generated using the plasmid lentiCRISPR (gift of 
Feng Zhang; Addgene plasmid # 52961) (22). Target sequences used were: 
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MRCKα1: GATTGGTCGAGGAGCTTTTG, MRCKα2: 
TGTCTGGAGAAGTGCGTTTG, MRCKβ1: TGTCGCGGCGCAGGGCCGAG, 
MRCKβ2: CGTGGCCGAGTTCCTCGAGT. To generate double MRCKαβ knockout 
MDA MB 231 D3H2LN Luc cells, all 4 targeting sequences were used together. 
 
Western blots 
Cell lysates and immunoblot analysis were performed as described in (19). The 
following antibodies were used: rabbit anti-MRCKα pS1003 antibody raised by 
Eurogentec using the peptide AcNH-KGCPG-S(PO3H2)-TGFPP-CONH2, rabbit anti-
pMLC2 Thr18/Ser19 (#3674; Cell Signaling Technology), mouse anti-
MRCL3/MRLC2/MYL9 (sc-28329; Santa Cruz Biotechnology), mouse anti α-tubulin 
(T9026; Sigma), rabbit anti-ERK2 (Chris Marshall, Institute of Cancer Research, 
London UK), mouse anti-MRCKα (H00008476-M01; Abnova), mouse anti-MRCKβ 
(H00009578-M03; Abnova), mouse anti-MRCKαβ (MANDM1 6G8; Glenn Morris, 
Centre for Inherited Neuromuscular Disease, Oswestry UK) (23), mouse anti-ROCK1 
(BD‐611136; BD Biosciences), mouse anti-ROCK2 (BD‐61062; BD Biosciences), 
mouse anti-Cas9 (C15200229; Diagenode), mouse anti-FLAG (F4042; Sigma). 
Secondary antibodies used were: goat anti-mouse IgG Dylight 800 (35521; Thermo 
Scientific), goat anti-rabbit IgG AlexaFluor 680 (A12076; Invitrogen), goat anti-rabbit 
IgG IR Dye 800 CW (926-32211; LI-COR Biosciences), goat anti-mouse IgG IR Dye 
680 (926-68020; LI-COR Biosciences). 
 
Protein crystallization, data collection and structure determination 
Expression, purification and crystallization of the kinase domain of human MRCKβ 
as well as subsequent ligand soaks were performed as described previously (19). 
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After a brief soak in mother liquor supplemented with 20% ethylene glycol, crystals 
were flash-frozen to 100K and data were collected at beamlines i24 (BDP8900 
complex) and i02 (BDP9066 complex) of Diamond Light Source (Didcot, UK). Data 
were processed with XDS (24) and scaled using Aimless (25) (via xia2 (26) in the 
case of the BDP8900 complex) to resolutions of 1.68Å (BDP8900) and 2.00Å 
(BDP9066), then phased by manual placement of the protein component of the 
MRCKβ ADP complex structure (PDB ID 4UAK) followed by rigid body refinement 
with REFMAC (27). Models were improved through cycles of model building with 
Coot (28) and refinement with REFMAC. Ligand restraints and starting coordinates 
were generated using PRODRG (29), model validation was carried out using Coot 
and MolProbity (30). Data collection and final model statistics are presented in 
Supplemental Table 1. All structural images were rendered using PyMOL (PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC). 
 
Cell viability 
To determine the effect of BDP9066 on SCC12 cell viability, a dose curve was 
established using the CellTiter‐Glo Luminescent Cell Viability Assay (Promega). 
1.5 × 104 cells were plated per well of a 96‐well plate. After 24 hours, medium was 
removed and cells cultured for 24 hours with medium supplemented with DMSO 
vehicle or a dose range of BDP9066. Measurements were taken using a Tecan 
Safire plate reader.  
 
Operetta high content morphology analysis 
SCC12 cells were plated at 1.5 × 104 per well of a 96‐well plate. After 24 hours, 
medium was removed and cells were cultured for 2 hours with medium 
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supplemented with DMSO vehicle or a dose range of BDP9066. Cells were fixed 
with 4% paraformaldehyde in PBS for 15 minutes, permeabilized with 0.5% (v/v) 
Triton-X100 in PBS for 15 minutes and blocked in 1% (w/v) BSA in PBS for 30 
minutes. Cells were stained with Alexa 568 Phalloidin (A12380; ThermoFisher 
Scientific), DAPI (D9564; Sigma) and Deep Red Whole Cell Stain (H32721; 
ThermoFisher Scientific). The cells were imaged and analyzed using the Operetta 
high content imaging system. 
 
Immunofluorescence 
SCC12 cells were seeded onto glass coverslips and allowed to settle and grow 
overnight. Next day, medium was replaced with medium containing 1 µM BDP9066 
or DMSO vehicle. After 1 h of drug treatment, cells were fixed in 4% 
paraformaldehyde/PBS for 15 min and permeabilized with 0.5% Triton X-100/PBS 
for 5 min. F-actin was visualized by incubation with Alexa Fluor 488 Phalloidin 
(Thermo Fisher Scientific). Cells were mounted with ProLong Diamond including 
DAPI (Molecular Probes). Images were taken on a Zeiss 710 confocal microscope. 
 
Random migration  
SCC12 cells were plated at 2× 104 per well of an Essen Bioscience ImageLock 96 
well plate. After 24 hours of culture, medium was replaced with medium 
supplemented with either DMSO vehicle or 0.4 μM BDP9066. After 1 hour, plates 
were placed in an Incucyte Zoom apparatus to image cells every 15 minutes for 6 
hours. Image stacks were analyzed using ImageJ with the Manual Tracking plugin, 
and 120 cells in 6 different wells per condition were tracked. Data was plotted using 
ImageJ with the Chemotaxis and Migration tool. 
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Plasmids and protein production 
The pEF-FLAG-MRCKα plasmid containing N-terminal FLAG tagged full length 
MRCKα isoform b and the pEF-FLAG-MRCKα-K106M plasmid with a mutation of 
Lysine 106 to Methionine (K106M) were gifts from Simon Wilkinson (University of 
Edinburgh, Edinburgh UK). The pEF-FLAG-MRCKα-S1003A was generated by site 
directed mutagenesis of pEF-FLAG-MRCKα using Quickchange II XL (Agilent 
Technologies) following manufacturer recommendations. Primers used were: 
S1003A forward: aaaaaggatgtcctggtgcaactggctttccacct, S1003A reverse: 
aggtggaaagccagttgcaccaggacatccttttt. The pEF-FLAG-MRCKα∆C plasmid was 
created using sited directed mutagenesis of pEF-FLAG-MRCKα by inserting a stop 
codon after nucleotide 4860 corresponding to amino acid 1620. The resulting protein 
is 100 amino acids shorter than full length MRCKα isoform b. The primers used 
were: MRCKα∆C forward: gagtgctagcagtggctgattgtcagcaaggtcat, MRCKα∆C 
reverse: atgaccttgctgacaatcagccactgctagcactc. 
A pGEX2T-MLC2 plasmid was used for bacterial production of recombinant 
MLC2. BL21 bacteria were transformed with pGEX2T-MLC2 and grown on ampicillin 
plates, 1 colony was picked and cultured overnight in 100 mL of LB medium 
supplemented with ampicillin. The culture was diluted 1 in 10 (30 mL in 300 mL of LB 
+ ampicillin) and cultured for 1 hour, then 50 µM IPTG was added and incubated for 
3 hours. Cultures were centrifuged at 4000 rpm for 15 minutes at 4°C and the pellet 
lysed in Tris buffered saline (TBS) with 5 mM MgCl2, 1 mM DTT, 1 mM PMSF. 
Lysates were sonicated 3 times for 1 minute on ice and then centrifuged at 10,000 
rpm for 10 minutes at 4°C. The supernatant was collected and used for in vitro MLC2 
phosphorylation assays. 
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MRCKα transfection and immunoprecipitation 
HEK293 human embryonic kidney cells were plated at 1× 106 per 10 cm culture dish. 
The next day, medium was replaced with OPTIMEM, and after 1 hour cells were 
transfected in OPTIMEM with 10 μg of pEF-FLAG-MRCKα, pEF-FLAG-MRCKα∆C, 
pEF-FLAG-MRCKα-K106M or pEF-FLAG-MRCKα-S1003A using Fugene HD 
(Promega). After 6 hours, medium was replaced with DMEM + 10% fetal calf serum 
(FCS) + L-glutamine. 2 days after the transfection, cells were placed on ice, washed 
in ice cold PBS and lysed in 1 mL of ice cold lysis buffer (TBS with 1 mM EDTA, 1% 
(v/v) Triton-X100, 1mM PMSF, 1X Complete protease inhibitor (Roche), 20 mM NaF, 
20 mM β-glycophosphate, 0.2 μM Na3VO4, 20μg/mL Aprotinin). Lysates were then 
incubated on a rotating wheel for 30 minutes at 4°C, then centrifuged at 13,200 rpm 
for 10 minutes at 4°C and supernatants collected. The lysates were then either used 
directly for western blots or MRCKα was immuno-precipitated. 
For immunoprecipitation, lysates were incubated with anti-Flag agarose beads 
(A2220; Sigma) on a rotating wheel for 2 hours at 4°C. Beads were washed 3 times 
in lysis buffer by successive centrifugations at 3,000 rpm for 1 minute at 4°C. For in 
vitro MRCKα auto-phosphorylation, phosphatase assays and MLC2 phosphorylation 
assays, beads were used as described in their respective sections. For mass 
spectrometry and western blots, beads were boiled at 95°C in 1% (w/v) SDS for 5 
minutes, centrifuged at 3,000 rpm for 2 minutes and supernatants collected. 
 
Cell treatment with MRCK inhibitors 
SCC12 cells were plated at 5 × 105 per well of a 6 well plate. After 24 hours, medium 
was replaced with medium supplemented with DMSO or a dose range of BDP9066. 
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After 2 hours, cells were washed in PBS and lysed in 1% (w/v) SDS, 50 mM Tris-
HCl, pH 7.4. Lysates were passed through QIAshredder spin columns (79654; 
Qiagen) and analyzed by SDS-PAGE. 
HEK293 cells were transfected with pEF-FLAG-MRCKα. After 48 hours, 
medium was replaced with medium supplemented with either DMSO, 3 μM 
BDP5290 or 1 μM BDP9066. After 2 hours, cells were washed in PBS and lysed in 
1% (w/v) SDS, 50 mM Tris-HCL pH 7.4. Lysates were passed through QIAshredder 
spin columns and analyzed by SDS-PAGE. 
MDA MB 231 cells expressing doxycycline inducible ROCK1, ROCK2 or 
MRCKβ kinase domains were plated at 1.1 x 105 per well of a 12 well plate. After 24 
hours, cells were treated with 1 µg/ml doxycycline for 18 hours to induce kinase 
domain expression and then tested with BDP8900 or BDP9066 at the concentrations 
indicated for 60 minutes. Cells were then washed with PBS and lysed with Tris-SDS 
lysis Buffer (50 mM Tris-HCl Ph 7.4, 0.5% (v/v) SDS, 1x PhosStop Inhibitors (04 906 
837 001; Roche) and 1x Complete Protease Inhibitors (04 693 124 001; Roche). 
Whole cell lysates were clarified by passing through QIAshredder spin columns and 
analyzed by SDS-PAGE. 
 
Mass spectrometry  
Full length MRCKα isoform b and full length MRCKα isoform b K106M were 
expressed in HEK293 cells and immunoprecipitated with FLAG antibody in triplicate 
experiments. Samples were run on SDS-PAGE and gels stained using Instant Blue 
(Expedeon). MRCK bands were excised and digested with trypsin (Promega) as 
previously described (31) 
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Protein tryptic digests were separated by nanoscale C18 reverse-phase liquid 
chromatography using an EASY-nLC II (Thermo Scientific) coupled on-line to a 
Linear Trap Quadrupole (LTQ) Orbitrap Velos mass spectrometer (Thermo 
Scientific) via a nanoelectrospray ion source (Sonation). The mass spectrometer was 
operated in data-dependent acquisition. Fragmentation was performed on the ten 
most intense ions using collision-induced dissociation (CID) with multistage 
activation enabled and higher energy collision dissociation (HCD) in two separated 
acquisitions.  
Raw data were processed with MaxQuant version 1.5.5.1 (32). Andromeda 
(33) peak list files (.apl) were converted to Mascot generic files (.mgf) using APL to 
MGF Converter (www.wehi.edu.au/people/andrew-webb/1298/apl-mgf-converter). 
MGF files were searched using Mascot (Matrix Science, version 2.4.1), querying the 
UniProt Homo sapiens database (09/07/2016; 92,939 entries) plus an in-house 
database containing common proteomic contaminants and the MRCKα K106M 
sequence. Mascot was searched assuming trypsin digestion, allowing two maximum 
missed cleavages, and with fragment ion and parent ion mass tolerances of 0.1 Da 
and 15 ppm, respectively. The iodoacetamide derivative of cysteine was specified in 
Mascot as a fixed modification. Methionine oxidation, and serine, threonine or 
tyrosine phosphorylation were specified in Mascot as variable modifications. MS/MS 
phosphopeptide data were manually curated with Xcalibur Qual Browser version 2.2 
(Thermo Scientific), and the MS-Product utility of Protein Prospector v 5.12.4 
(prospector.ucsf.edu/) was used to generate theoretical product ions fragmentation 
series. 
Raw msms.txt data files from MaxQuant and Mascot DAT files were imported 
into Skyline to build a library of MRCKα peptides. Extracted ions chromatograms 
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(XICs) of the 3 main isotopic peaks (30 K resolution at 400 m/z) of precursor ions 
from unmodified and phosphorylated MRCKα peptides that carried 2+ and 3+ charges 
were used for quantification of autophosphorylation sites. The peak areas of 
phosphopeptide 999-1009 that were measured in the 3 replicate experiments were 
normalized to “Global Standard” areas derived from the unmodified MRCKα tryptic 
peptides 310-315, 1113-1122 and 1268-1286. 
In vitro MRCKα assays 
For treatments with phosphatase and in vitro autophosphorylation, full length 
MRCKα or mutants bound to anti-FLAG beads were resuspended in 100 μL of 
phosphatase buffer with lambda protein phosphatase (P0753; New England Biolabs) 
following manufacturer’s instructions and incubated with constant agitation at 30°C 
for 1 hour. For samples treated for in vitro autophosphorylation and activity assays, 
beads were washed 3 times in PBS and 1 time in kinase buffer (20 mM Tris-HCl pH 
7.4, 0.5 mM MgCl2, 0.01% (v/v) Tween20, 1 mM DTT). For autophosphorylation, the 
beads were re-suspended in 98 μL of kinase buffer supplemented with 2 μL of 5 mM 
ATP. For MLC2 phosphorylation assays, the beads were resuspended in 94 μL of 
kinase buffer supplemented with 2 μL of 5 mM ATP and 4 μL of MLC2. For CDC42 
assays, the beads were resuspended in 97 μL of kinase buffer supplemented with 2 
μL of 5 mM ATP and 1 μg of constitutively active CDC42 Q61L (Cytoskeleton, Inc. 
Cat. # C6101). The beads were then incubated with constant agitation at 30°C for 1 
hour. To stop the reactions, 100 μL of boiling 2% (w/v) SDS was added to samples, 
and reactions were incubated for 5 minutes at 95°C. Samples were centrifuged at 
3,000 rpm for 2 minutes and supernatants were collected and analyzed by western 
blot. 
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In vitro 32P incorporation 
Immunoprecipitated full length MRCKα and MRCKα K106M bound to anti-FLAG 
beads were resuspended in kinase buffer supplemented with γ[32 P]-labelled ATP 
with constant agitation at 30°C for 1 hour. Samples were washed 3 times in kinase 
buffer. Beads were resuspended in 50 μL of boiling 1% (w/v) SDS and incubated for 
5 minutes at 95°C. Samples were then run on SDS-PAGE, gel was stained with 
Instant Blue (Expedeon) and an autoradiograph collected.  
 
Dot blots and peptide competition 
Two peptides including MRCKα isoform b S1003 were synthetized by Eurogentec. 
One peptide contained phosphorylated serine (P) = AcNH-KGCPG-S(PO3H2)-TGFPP-
CONH2, the other contained non-phosphorylated serine (U) = AcNH-KGCPG-S-TGFPP-
CONH2. A dose range of peptides P and U were spotted on Protran nitrocellulose 
membrane (Sigma) pre-soaked in TBS + 0.01% (v/v) Tween20 (TBST), and the 
membrane was dried. When dry, the membrane was blocked in TBST + 0.5% (w/v) 
BSA for 30 minutes and incubated overnight at 4°C with MRCKα-pS1003 antibody at 
1:500 in TBST + 0.5% (w/v) BSA. Blots were imaged using SuperSignal™ West 
Femto Maximum Sensitivity Substrate (34095; Thermo Scientific). 
For peptide competition, 2 μL of MRCKα-pS1003 antibody in 1 mL of TBST + 
0.5% (w/v) BSA was incubated with 4 ng peptide P or 4 ng peptide U, and incubated 
for 2 hours. Solutions were centrifuged at 13,200 rpm for 10 minutes, supernatants 
collected and re-incubated with 4 ng peptide P or 4 ng peptide U for 2 hours. The 
solutions were centrifuged at 13,200 rpm for 10 minutes. Antibodies were then 
applied to western blots of immunoprecipitated MRCKα. 
 
Research. 
on February 1, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 30, 2018; DOI: 10.1158/0008-5472.CAN-17-2870 
16 
 
Cancer cell line screen 
The Translational Cancer Genomics team at the Wellcome Trust Sanger Institute 
screened 757 cancer cell lines with BDP8900 and BDP9066. Cells were seeded in 
1536 well plates and compounds were screened using a 7-pt dose response curve 
and half-log compound dilution series. Cell viability was measured using CellTitre 
Glo (Promega). Detailed information about the screening process can be obtained at 
www.cancerrxgene.org  
 
Immunohistochemistry 
Formalin‐fixed, paraffin‐embedded sections were dewaxed and rehydrated. Antigen 
retrieval was performed in a boiling water bath with 10 mM citric acid buffer at pH 6 
for 20 minutes. After cooling, endogenous peroxidase was blocked with 3% (v/v) 
H2O2 for 15 minutes. Sections were subsequently blocked in PBS + 0.5% (v/v) goat 
serum for 30 minutes. Primary antibodies were incubated overnight at 4°C in PBS + 
0.5% (v/v) goat serum: rabbit anti-MRCKα (ab96659; Abcam) was used at 1:100, 
rabbit anti-MRCKβ (HPA022821; Sigma) was used at 1:1000, rabbit anti-MRCKα 
pS1003 was used at 1:50. Envision + System‐HRP labeled Polymer (Dako) and 
Liquid DAB + Substrate Chromogen (Dako) were ]used for visualization. For staining 
quantifications, sections were imaged using a Leica SCN 400f scanner. Intensity 
thresholds were defined for absence of staining, low intensity staining, medium 
intensity staining and high intensity staining of MRCKα pS1003 IHC pictures using 
Leica Slidepath image analysis software. Areas of normal skin and of papilloma were 
selected for each sample and analyzed. Automatic cell detection was performed and 
the cytoplasmic intensities of the MRCKα pS1003 staining were measured. 
Histoscores were measured by multiplying the percentage of low intensity staining in 
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the area by 100 and adding it to the percentage of medium intensity staining in the 
area multiplied by 200 and adding it to the percentage of high intensity staining in the 
area multiplied by 300.    
  
 
Mouse models 
Parental MDA MB 231 D3H2LN Luc cells or MRCKαβ KO cells (3.5 x106) were 
subcutaneously injected in the right flank of CD-1 immunocompromised nude mice. 
Mice were culled and sampled 2 weeks post-injection before tumors reached 12 mm 
diameters. 
Mouse genetic skin cancer models expressing activated Hras alone, or with c-
Fos plus conditional deletion of Pten, in epidermal keratinocytes form papillomas that 
convert to carcinoma as described (34-36). 
To study the effect of BDP9066 on MRCKα pS1003 staining in mouse skin, 5 
FVB mice were treated topically with 50 μL of 80% (v/v) DMSO (vehicle) and 5 FVB 
mice were treated topically with of 25 μg of BDP9066 in 50 μL 80% (v/v) DMSO. 
Treatments were applied 4 times per mouse over 2 days. Mice were culled 2 hours 
after final treatment. Skin and blood BDP9066 concentrations were measured by 
Pharmidex. To study BDP9066 pharmacokinetics on mouse skin and blood, FVB 
mice were treated topically once with 10 μg or 25 μg BDP9066 in 80% (v/v) DMSO, 4 
times daily with 25 μg BDP9066 in 80% (v/v) DMSO, or 8 times daily (4 successive 
days on, 2 days off, then 4 days on) with 80% (v/v) DMSO or 25 μg BDP9066 in 80% 
(v/v) DMSO. Mice were culled 2 hours, 4 hours, 8 hours or 24 hours after final 
treatment. Skin and blood BDP9066 concentrations were measured by Pharmidex. 
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For DMBA/TPA experiments, 40 FVB mice were treated topically with 25 μg 
DMBA in acetone on day 1. From day 5, 4.7 μg TPA in acetone was applied 3 times 
weekly. From day 5, 20 mice were treated with 25 μg BDP9066 in 50 μL 80% (v/v) 
DMSO and 20 mice were treated with 50 μL 80% (v/v) DMSO 5 times per week. 
Experimenters were fully blinded to the identity of treatment groups. Mice weights 
and general conditions were monitored at least 2 times per week, tumor sizes and 
numbers were recorded weekly. Mice were culled when papillomas reached 12 mm 
in diameter. Analysis of tumor volume and papilloma numbers were performed 
blinded to the identity of treatment groups. Skin and blood BDP9066 concentrations 
were measured by Pharmidex. 
All mouse experiments have been conducted in accordance with UK Home Office 
regulations, and with the approvals of the Cancer Research UK Beatson Institute Animal 
Care and Use Committee (IACUC) and University of Glasgow Ethical Review. 
 
Statistics 
Data analysis was performed using GraphPad Prism. Statistical tests used for each 
data set are indicated in respective figure legends. 
 
Results 
Discovery and characterization of MRCK inhibitors BDP8900 and BDP9066. 
A focused fragment library was screened using an MRCKβ biochemical assay 
(16,19), and structure-guided elaboration of a ligand-efficient 7-azaindole-3-
carbonitrile fragment hit (Figure 1A), prioritizing the identification of MRCK-selective 
inhibitors, led to the discovery of BDP8900 and BDP9066 (Figure 1A). Synthesis 
routes and methods for BDP8900 and BDP9066 will be described in a subsequent 
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manuscript (in preparation). When the enzyme activities of MRCKα, MRCKβ, and the 
closely related AGC family kinases ROCK1 and ROCK2, were assayed in vitro at 1 
µM ATP, which approached ATP Km values for these kinases under identical assay 
conditions (Supplemental Table 2), both compounds induced dose-dependent 
inhibition with greater selectivity for the MRCK kinases relative to ROCK kinases 
(Figure 1B and 1C). Using experimentally determined ATP Km values and the 
Cheng-Prusoff equation (37), calculated Ki values revealed affinities for MRCKα and 
MRCKβ that were 318 to 2371 fold greater for both compounds than for ROCK1 or 
ROCK2 (Supplemental Table 2). Inhibition of myosin light chain phosphorylation 
(pMLC2) in MDA MB 231 human breast cancer cells, engineered to express 
tetracycline-inducible MRCKβ, ROCK1, or ROCK2 kinase domains (19), by 
BDP8900 was >562 times more selective for MRCKβ relative to ROCK1 or ROCK2 
(Figure 1D), and by BDP9066 was >100 times more selective for MRCKβ relative to 
ROCK1 or ROCK2 (Figure 1E). 
 To extend selectivity profiling, a larger panel of 115 kinases was screened 
with 1 µM BDP8900 or BDP9066 either for inhibition of kinase activity at the 
apparent Km for ATP of each kinase, or for competitive inhibition of binding to the 
ATP site (Supplemental Table 3). Kinase inhibition results were mapped onto an 
annotated human kinase phylogenetic tree (38) using KinMap (39) (Supplemental 
Figure 1), and displayed as a heat map (Figure 2A). The majority of kinases were 
unaffected by BDP8900 or BDP9066 (indicated by green circles with labels, with 
>75% inhibition (red circles) of the AGC kinases PKCγ and DMPK by BDP8900 
(Supplemental Figure 1A, Figures 2A and 2B), and ROCK1, ROCK2, CDK2/Cyclin 
A, CDK9/(Cyclin K or Cyclin T1), PKCα, TSSK1 (STK22D) and DMPK by BDP9066 
(Supplemental Figure 1B, Figures 2A and 2B). To more precisely characterize the 
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selectivity of BDP8900 and BDP9066, dose-response assays were performed 
against kinases identified by the screen as comparatively sensitive (Figure 2B, red 
dots). Under the assay conditions, BDP8900 and BDP9066 were markedly selective 
against all kinases tested (Figures 2C and 2D). Using ATP Km values and the 
Cheng-Prusoff equation (37), calculated Ki values from this screen revealed 
minimum fold-selectivity for MRCKβ that was 43 times greater for BDP8900 
(Supplemental Table 4) and 27 times greater for BDP9066 against all kinases tested 
(Supplemental Table 5). 
The myotonin-protein kinase, also known as DMPK, has high homology to 
MRCKα and MRCKβ with over 61% amino acid identity in its kinase domain 
compared to both their kinase domains (80.8% identity between MRCKα and 
MRCKβ). A competitive LanthaScreen Eu time-resolved fluorescence resonance 
energy transfer (TR-FRET) kinase binding assay in which BDP8900 and BDP9066 
were assayed in vitro for displacement of a fluorescent tracer that binds to the DMPK 
ATP-binding site with 43 nM Kd (Figure 2E) yielded 0.80 nM (BDP8900) and 0.98 nM 
(BDP9066) Kd values using the Cheng-Prusoff equation (37). 
Given the >1.0 Hill slopes (~1.9) for the MRCKβ inhibition curves for 
BDP8900 (Figure 2C) and for BDP9066 (Figure 2D), and the lower apparent 
potencies of both MRCK inhibitors in this assay format relative to the potencies 
observed assay using optimized conditions established in-house (Figures 1B and 
1C), the selectivities of BDP8900 and BDP9066 were likely underestimated. Plotting 
the natural log Ki values determined in-house (Figure 2F, red dots) against out-
sourced values (Figure 2F, black dots) indicated that the differences between in-
house and outsourced Ki values for ROCK1 inhibition were only 4.4-fold for 
BDP8900 and 2.9-fold for BDP9066, but for MRCKβ differed by 41-fold for BDP8900 
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and 59-fold for BDP9066, consistent with on-target compound potencies being 
undervalued due to insufficient sensitivity of the out-sourced assays. While 
numerous parameters were rigorously optimized to maximize the sensitivity of the in-
house kinase assays, including detection method, pH, MgCl2 and substrate 
concentrations, the out-sourced kinase assay conditions were not necessarily 
optimized for each kinase, but were generic for wide use against many different 
kinases. When compared against MRCKβ Ki values determined in-house (Figure 2F, 
red dots), the affinity of BDP8900 was more than 2083 times greater, and of 
BDP9066 was more than 1635 times greater, relative to all other kinases tested for 
inhibition of activity (Figure 2F, black dots), and 33-fold higher than the DMPK Kd 
determined for BDP8900 and 42-fold higher than for BDP9066 (Figure 2F, purple 
dot). Taken together, these results reveal that BDP8900 and BDP9066 are potent 
and highly selective inhibitors of MRCK with robust on-target actions in vitro and in 
whole cells. 
 
Structures of BDP8900 and BDP9066 associated with MRCKβ kinase domain. 
To investigate the binding mode of these azaindole compounds, crystal structures of 
MRCKβ in complex with BDP8900 and BDP9066 were determined to 1.68Å and 
2.00Å resolutions, respectively (Supplemental Table 1). The overall protein 
conformations in these complexes were essentially identical to those seen 
previously, with RMSD values after superposition onto all PDB-deposited MRCKβ 
structures (16,19) ranging from 0.5Å to 1.5Å for ≈395 Cα atoms. As noted previously 
(19), the glycine-rich loop (specifically residues 84–88) showed most conformational 
diversity. While in the MRCKβ·BDP9066 complex structure it was in the closed state 
observed for other inhibitor complexes (16,19), the MRCKβ·BDP8900 complex 
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showed an open conformation similar to that described for the ADP complex 
structure (19). This was surprising given the similarity between the two compounds 
in structure (Figure 1A) and binding mode (see below). It should be noted that in 
both complexes there were hints of electron density supporting the ‘other’ loop 
conformation, suggesting that the glycine-rich loop is somewhat flexible and able to 
switch between closed and open states in the presence of azaindole inhibitors. It is 
possible that crystal-to-crystal variation, rather than ligand features, determine the 
apparently preferred state. 
A second region of conformational divergence was formed by the C-terminal 
end of the activation loop (around Val235) and the αEF/αF loop (around Met255), 
though again both these loops were relatively flexible in all MRCKβ ligand complexes 
and there is no clear connection between the contents of the ATP-binding site and 
the major loop conformations. 
BDP8900 and BDP9066 adopt highly similar poses in the ATP-binding site 
(Figures 3A and 3B): the all-atom coordinate RMSD for the two ligands after 
superposition of the two complex structures on the protein residues highlighted in 
Figure 3A was 0.105Å for 21 comparable atoms (i.e. excluding the 
thiazole/pyrimidine). The azaindole acts as the hinge binder, forming hydrogen 
bonds with the backbone carbonyl of Asp154 and the backbone amine of Tyr156. 
Both ligands preserved the two ‘pocket waters’ seen in the BDP5290 complex (19) 
and satisfy the hydrogen bonding potential of the outer (left in Figures 3A and 3B) 
water by accepting an H-bond to the thiazole (BDP8900) or pyrimidine (BDP9066) 
nitrogen. In addition, the second pyrimidine nitrogen of BDP9066 accepts a 
hydrogen bond of relatively poor geometry from Lys105. 
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The spiro moiety of the azaindole ligands provides a ‘plug’ for the ATP-binding 
site opening, interacting with residues around the glycine-rich loop (Ile82, Gly83, 
Arg84, Val90), the catalytic loop (Asp204, Asn205, Leu207) as well as Phe370 
(Figure 3C). In the MRCKβ·BDP8900 complex, the open conformation of the glycine-
rich loop results in a loss of the interaction with Arg84. In addition to the mostly 
hydrophobic direct protein-ligand contacts, the ring nitrogen of the distal piperidine 
formed hydrogen bonds with (and orders) two water molecules, one of which (on the 
right in Figure 3C) provided indirect interactions with the backbone of Asp204 and 
the side chain of Asp160. The other water was more exposed to bulk solvent and 
accordingly appears less well bound and less consistent in its interactions, which can 
involve Asp204 and (via additional ordered waters) Arg84, Asn205 and Asp218. 
Comparing the binding modes of the azaindole ligands and the previously 
described pyrazole amide BDP5290 (19) reveals that most binding interactions are 
maintained across compound series despite their unrelated chemical structures and 
binding modes (Figure 3D). The azaindole and pyrazole cores form equivalent 
interactions with the hinge. Pocket water hydrogen bonding duties fulfilled by the 
amide linker in BDP5290 are taken over by the heterocyclic 3-substituent (thiazole or 
pyrimidine), which also partly fills the space occupied by the chloropyrazole of 
BDP5290. The diazaspiro[5.5]undecane substituent of the azaindole compounds 
provided an approximate replacement for the piperidine of BDP5290, though it 
appears that the shift in location and nitrogen position of the terminal piperidine 
moiety allowed BDP8900/9066 to form more extensive interactions with the protein, 
which may contribute to the higher affinity of these compounds for MRCKβ. Another 
notable difference between the two series is that, unlike the 2-pyridylpyrazole of 
BDP5290, the smaller azaindole of BDP8900/9066 did not displace the Phe370 side 
Research. 
on February 1, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 30, 2018; DOI: 10.1158/0008-5472.CAN-17-2870 
24 
 
chain on binding (Figure 3D), avoiding energetic penalties associated with this 
conformational change and preserving a more compact ATP-binding site 
conformation for the spiro moiety to interact with, which could contribute to the 
improved affinity of the azaindoles compared to BDP5290. 
We previously proposed the ligand interaction with the pocket waters as a 
determinant of selectivity for MRCK over ROCK, and this appears to hold true when 
comparing BDP8900 and BDP9066. The hydrogen bonding geometry between the 
thiazole of BDP8900 and the outer pocket water is closer to ideal than that seen for 
the pyrimidine of BDP9066, and correspondingly the former compound exhibit 
greater selectivity. 
 
Effect of MRCK inhibitors on cancer cell line viability. 
To identify cancer cell lines with significant sensitivity to the anti-proliferative effects 
of MRCK inhibitors as single agents, 757 cancer cell lines were screened using a 7-
point dose range up to 10 µM of either BDP8900 or BDP9066, and viability 
monitored after 72 hours as described in (40). By comparing cell line EC50 values 
within a given cancer type against all cancer cell lines (Supplemental Table 6), 
significantly (p<0.05) sensitive (green) and resistant (red) cancer types were 
identified. Figure 4A shows natural log EC50 values (µM) of BDP8900 for each cell 
line within each cancer type, with purple lines indicating mean EC50, arranged from 
low to high mean EC50. Relative to the effect of BDP8900 on all cancer cell lines 
together (blue), there were 10 cancer types significantly sensitive and 6 cancer types 
significantly resistant. Similarly, 8 cancer types were significantly sensitive and 4 
were significantly resistant to BDP9066 relative to all cancer cells (Figure 4B). When 
the mean EC50 values of BDP8900 and BDP9066 for each cancer type were plotted, 
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Deming regression analysis revealed a strong correlation (p<0.001) and a line slope 
that approached 1.0, with common sensitive cancer types (green dots) and resistant 
cancer types (red dots) relative to all cancers (blue dots) indicated (Figure 4C). 
Plotting the EC50 values of BDP8900 and BDP9066 for each cell line also revealed a 
strong correlation (p<0.0001) by Deming regression and a line slope that 
approached 1.0 (Supplemental Figure 2). These results strongly support the 
conclusion that the effect of both inhibitors on cancer cell proliferation is due to a 
common mechanism of action that is highly likely to be on-target inhibition of MRCK 
activity. Interestingly, all 8 cancer types sensitive to both BDP8900 and BDP9066 
were hematological cancers, with 2 additional blood cancers being significantly 
sensitive to one compound and others clustering, albeit not reaching statistical 
significance, to the sensitive end of the rankings. 
 
MRCKα S1003 autophosphorylation as a biomarker of activity. 
An additional strategy to identify cancer types that potentially would benefit from 
MRCK inhibitor treatment is to search for indications of increased MRCK signaling. 
By identifying phosphorylation sites that could be used as surrogate markers of 
activity, it was previously shown that ROCK1 S1333 phosphorylation (41) and 
ROCK2 S1366 phosphorylation (42) were associated with kinase activity, and that 
phosphorylation-state sensitive antibodies could be used to assess ROCK activity in 
clinical cancer samples (43). When wild-type MRCKα, or a kinase-dead version with 
a K106M mutation that prevents ATP binding, were expressed and 
immunoprecipitated from HEK293 cells (Figure 5A, left panel), in vitro kinase assays 
with [γ-32P] ATP revealed considerable 32P labelling of wild-type MRCKα, but not 
MRCKα K106M (Figure 5A, right panel). To identify autophosphorylation sites, wild-
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type MRCKα and MRCKα K106M were expressed and immunoprecipitated from 
HEK293 cells (Figure 5B, left panel), and phosphorylations measured by mass 
spectrometry (Figure 5B, right panel). A total of 22 phosphorylations were identified 
on MRCKα (Supplemental Table 7), of which 8 were not detected in MRCKα K106M, 
including S1003 (Figure 5B, y7 m/z peaks in right panel; Supplemental Table 8), 
consistent with these phosphorylations being autocatalyzed. S1003 is located 
between the coiled-coil (CC) and phorbol ester/diacylglycerol-binding C1 domains 
(Figure 5B, right panel inset). A comparison with MRCKβ revealed no conservation 
of MRCKα autophosphorylated residues (Supplemental Figure 3). 
A polyclonal phosphospecific antibody against pS1003 was raised using the 
phospho-peptide (P) AcNH-KGCPGpSTGFPP-CONH2. Dot blots with varying quantities 
(10-500 pg) of phosphorylated (P) or unphosphorylated peptides (U) confirmed the 
phosphorylation-selective binding of this antibody (Figure 5C). Detection of 
immunoprecipitated FLAG-tagged MRCKα by western blotting was blocked by pre-
incubation of the antibody with phosphopeptide P, but not peptide U (Figure 5D). 
Incubation of immunoprecipitated FLAG-tagged MRCKα with lambda phosphatase 
also led to loss of pS1003 antibody reactivity (Figure 5E). Immunoreactivity with the 
pS1003 antibody was detected on immunoprecipitated FLAG-tagged MRCKα, but 
not kinase-dead K106M or non-phosphorylatable S1003A mutants, consistent with 
this site being autophosphorylated (Figure 5F).  
To establish if MRCKα S1003 autophosphorylation could be used as a 
MRCKα activity biomarker, recombinant constitutively-active CDC42 Q61L was 
incubated with immunoprecipitated FLAG-tagged MRCKα, which resulted in a 
significant ~30% increase in S1003 autophosphorylation (Figure 5G). Treatment of 
HEK293 cells expressing FLAG-tagged MRCKα with DMSO vehicle, 3 µM BDP5290 
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(19) or 1 µM BDP9066 MRCK inhibitors blocked pS1003 immunoreactivity (Figure 
5H), indicating that the phospho-selective antibody could be used as a surrogate 
marker of MRCKα activity.  
To determine the mechanism of MRCKα S1003 autophosphorylation, a 
FLAG-tagged MRCKα mutant lacking the last 100 amino acids (MRCKα∆C), or the 
kinase-dead K106M mutant, were expressed and purified from HEK293 cells. 
Following FLAG-immunoprecipitation and lambda phosphatase treatment to reverse 
S1003 phosphorylation, purified proteins were incubated with Mg2+-ATP to allow 
autophosphorylation. While the faster-migrating MRCKα∆C was able to 
autophosphorylate S1003 in cis when alone or with K106M, there was no evidence 
of trans phosphorylation of the larger K106M mutant by active MRCKα∆C (Figure 5I). 
Therefore, MRCKα utilizes an intra-molecular mechanism for S1003 
autophosphorylation. When dephosphorylated MRCKα (Figure 5J, upper panel) was 
allowed to phosphorylate itself and recombinant MLC2 in the same in vitro reaction, 
both autophosphorylation (Figure 5J, lower left panel) and MLC2 phosphorylation 
(Figure 5J, lower right panel) were blocked by BDP9066, supporting the relationship 
between MRCKα S1003 autophosphorylation and kinase activity. 
To characterize whether S1003 autophosphorylation is required for substrate 
phosphorylation, FLAG-tagged MRCKα, kinase-dead K106M and non-
phosphorylatable S1003A mutants were immunoprecipitated from HEK293 cells and 
assayed for MLC2 phosphorylating activity in vitro. While kinase-dead K106M was 
significantly less active than wild-type MRCKα or the S1003A mutant, there was no 
significant difference in activity between wild-type MRCKα or the S1003A mutant 
(Figure 5K). These results indicate that S1003 autophosphorylation is not required 
for MRCKα activation and substrate phosphorylation. 
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MRCK expression and activation in mouse models of skin cancer. 
Analysis of publicly available human microarray data using Oncomine (44) revealed 
significantly elevated levels of both MRCKα and MRCKβ in human epidermal 
squamous cell carcinoma (SCC) relative to normal skin (Figure 5L) (45). Previous 
studies revealed a role for MRCKα in contributing to SCC in genetically modified 
(GM) mice expressing an oncogenic Hras transgene combined with Notch1 inhibition 
(46). To determine whether MRCKα and MRCKβ expression or activation were 
associated with SCC in additional GM mouse models, antibodies against MRCKα, 
MRCKα pS1003 and MRCKβ were first validated for immunohistochemistry (IHC) 
using MDA MB 231 D3H2LN human breast cancer cells (47) knocked out for 
MRCKα and MRCKβ by CRISPR/Cas9 (Supplemental Figure 4A). Parental and 
MRCKαβ knockout (KO) cells were grown subcutaneously in immunocompromised 
nude mice for 2 weeks. Sections of parental cell xenografts stained with the 3 
antibodies were positive, but staining was abrogated in sections of KO cell 
xenografts (Supplemental Figure 4B). Antibody phosphoselectivity was validated 
when MRCKα pS1003 staining of MDA MB 231 subcutaneous tumors was blocked 
by antibody preincubation with phosphopeptide P, but not unphosphorylated peptide 
U (Supplemental Figure 4C). 
 MRCKα, MRCKα pS1003 and MRCKβ immunoreactivity were examined in 
GM mouse SCC models expressing epidermis-targeted activated Hras alone (34), or 
in combination with epidermis-targeted transgenic c-Fos and conditional epidermal 
deletion of Pten (35), which give rise to stable papillomas that may stochastically 
convert to malignancy via additional events such as p53 loss (36). MRCKα was 
expressed at moderately high levels in benign Hras and Hras/c-Fos/Pten-/- tumors, 
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which increased further following malignant conversion to become strong and 
uniform in invasive SCC layers (Figure 5M). MRCKα pS1003 and MRCKβ were 
expressed at low levels in benign tumors with slight increases in early stage 
carcinomas (Figure 5M). MRCKα pS1003 expression was mainly confined to post-
mitotic, differentiating SCC layers, while MRCKβ displayed weak expression 
maintained in proliferative layers and strong expression in occasional invasive cells. 
The observations were similar in the 7,12-Dimethylbenz[a]anthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA) (DMBA/TPA) two-stage chemical 
carcinogenesis SCC model, with moderate to high levels of MRCKα and MRCKβ, 
and a restricted pattern of MRCKα pS1003 staining in post-mitotic differentiating 
SCC cells (Figure 5M). These results indicate that MRCKα and MRCKβ expression, 
and MRCKα activation are associated with mouse skin tumors induced by genetic 
modifications and chemical carcinogenesis.  
 
BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell 
carcinoma motility and invasion.  
It was previously determined that the phosphorylation of MLC and invasion of human 
SCC12 cells in an organotypic 3D collagen invasion model was sensitive to 
combined MRCKα/MRCKβ knockdown (18). Furthermore, the MRCK inhibitor 
BDP5290 also reduced MLC phosphorylation and inhibited SCC12 organotypic 
invasion (19). To investigate the effect of BDP9066 on pMLC2 in SCC12 cells, which 
express MRCK but no detectable DMPK (Supplemental Figure 5), varying BDP9066 
concentrations incubated with cells for 2 hours led to dose-dependent inhibition of 
MLC2 phosphorylation (Figure 6A, left) with an EC50 = 64 nM (Figure 6A, right), 
corresponding to a 5-fold increase in cellular potency relative to BDP5290 (19). 
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SCC12 cell viability following 24 hour treatment was unaffected by all BDP9066 
concentrations up to 0.5 µM (Figure 6B), despite maximal pMLC2 inhibition at this 
concentration (Figure 6A), with a 25% decrease in viability at 1 μM (Figure 6B). 
These results indicate that BDP9066 is relatively non-toxic at concentrations that 
profoundly inhibit substrate phosphorylation. 
Treatment of SCC12 cells with non-toxic 0.5 μM BDP9066 led to changes in 
cell morphology, with reduced proportions of regularly (rounded, few protrusions) 
shaped cells (Figure 6C, green cells), and increased irregularly (greater spreading, 
increased protrusions) shaped cells (Figure 6C, blue cells) as determined by high 
content imaging. By varying BDP9066 concentrations, it was determined that there 
was a parallel re-distribution from regular to irregular cell morphologies with similar 
EC50 values (Figure 6D). The proportion of elongated cells (Figure 6D, red cells) did 
not vary with BDP9066 concentrations (Figure 6D). When individual morphological 
parameters were examined, there were dose-dependent increases in cell length and 
width (Figure 6E, left panels), with dose-responsive changes in length exceeding 
width (Figure 6E, middle panel). The collective effect of these BDP9066 induced 
morphological alterations resulted in increased 2D cell area and decreased 
roundness (Figure 6E, right panels). 
Consistent with our previous observations using the MRCK inhibitor BDP5290 
(19), BDP9066 similarly reduced the bundling of filamentous actin at cortical and 
cytoplasmic regions (Figure 6F). To determine how MRCK inhibition affected cell 
motility, SCC12 cells were treated with DMSO vehicle control or non-toxic 0.4 μM 
BDP9066, and individual cells were tracked over 6 hours to quantify random 
migration. Scatterplots of cell paths showed marked reduction of cell motility induced 
by BDP9066 (Figure 6G). Mean cell velocity and accumulated distance travelled 
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were significantly reduced by 21%, while mean Euclidean distance travelled was 
significantly reduced by 18% (Figure 6H). No differences were observed for 
directionality of cell motility.  
The effect of non-toxic 0.4 μM BDP9066 was tested on organotypic invasion, 
in which the movement of SCC12 cells was measured from the surface downwards 
into a dense 3D rat tail collagen matrix that had been conditioned by cancer-
associated fibroblasts for 7 days prior to their removal (Figure 6I) (18). A significant 
50% decrease in the percentage of invading cells was observed for cells treated with 
0.4 μM BDP9066 relative to DMSO vehicle (Figure 6J). Taken together, the results 
indicate that in SCC12 cells BDP9066 potently inhibits MRCK at sub-micromolar 
levels, leading to inhibition of MLC phosphorylation, changes in cell morphology, and 
reduced cell motility and 3D collagen invasion, without significantly affecting cell 
viability. These findings are consistent with the previously reported inhibitory effects 
of MRCKα + MRCKβ knockdown by siRNA (18), and the MRCK inhibitor BDP5290 
(19) on SCC12 organotypic invasion. 
 
In vivo action of BDP9066 on mouse skin cancer. 
Having established that BDP9066 affects SCC tumor cell motility and invasion at 
sub-micromolar concentrations and viability at 1 µM in vitro (Figure 6), and that 
MRCKα, MRCKα pS1003 and MRCKβ levels were elevated in GM and chemically-
induced mouse models of skin cancer (Figure 5L), BDP9066 was evaluated for in 
vivo pharmacological proof-of-concept as an SCC chemotherapeutic agent. Topical 
application of 25 µg BDP9066 on FVB mouse skin twice per day for 2 days led to 26 
µM mean BDP9066 concentration in skin, but only 0.04 µM in blood (Figure 7A). 
BDP9066 application led to significantly reduced epidermal MRCKα pS1003 positive 
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staining (Figure 7B). To determine how repeated dosing would affect BDP9066 
accumulation and distribution, skin and blood concentrations were determined after 
10 μg was administered once, or 25 μg was repeated over 4 days (Figure 7C). 
Although relative to the single 10 μg dose, repeated 25 μg doses did result in 2.8 fold 
higher concentrations in skin (Figure 7C, left panel), and 4 fold higher concentrations 
in blood (Figure 7C, right panel), these differences were less than the 10 fold 
difference in total BDP9066 administered, indicating that compound accumulation 
was less than additive. To characterize clearance, BDP9066 was either given once 
at a 25 μg dose, or 8 times on a 4 days on, 2 days off, 4 days on schedule, and then 
compound concentrations were determined in skin and blood at 2, 4, 8 and 24 hours 
following the final dose. In either dosing regimen, over 16 μM BDP9066 was 
detected in skin 24 hours after final dosing (Figure 7D, left panel), while the low 
levels detected in blood were undetectable after 24 hours (Figure 7D, right panel). 
These results indicated that it was possible to achieve sustainable BDP9066 levels 
in mouse skin by repeated topical application, which were sufficient to induce 
phenotypic responses in squamous cell carcinoma cells in vitro, without significant 
compound accumulation following sequential administration. 
Given the MRCKα, MRCKα pS1003 and MRCKβ levels observed in skin 
tumors induced by the DMBA/TPA two stage chemical carcinogenesis protocol 
(Figure 5L), this model was selected to evaluate the in vivo efficacy of BDP9066. 
FVB mice were topically treated with 25 μg DMBA (Figure 7E, green arrow), then 
with 4.7 μg TPA 3 times per week (Figure 7E, purple arrow). In addition, mice were 
topically treated with 25 μg BDP9066, or an equal volume of DMSO vehicle control 
(Figure 7E, red arrow), 5 times per week (5 days on, 2 days off) for 14 weeks. At 
study end, skin papillomas in the BDP9066 treated group appeared visually smaller 
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than in the DMSO treated group (Figure 7F). Although total papilloma numbers per 
mouse were not different between the DMSO and BDP9066 treatment groups 
(Figure 7G), both the total tumor volume (Figure 7H, left panel) and average 
papilloma volume (Figure 7H, right panel) per mouse were significantly reduced in 
the BDP9066 treatment group. Topical BDP9066 application resulted in undetectable 
compound in blood, and >1 µM mean BDP9066 concentration in skin at 
experimental endpoint (Figure 7I), which was associated with significant decreases 
in MRCKα pS1003 immunohistochemistry staining (Figure 7J) and reduced 
histoscores both in the treated skin area (Figure 7K, left panel) and in papillomas 
(Figure 7K, right panel). These results provide pharmacological proof-of-concept 
evidence indicating in vivo therapeutic actions of BDP9066. 
 
Discussion 
The small molecule inhibitors BDP8900 and BDP9066 are the most potent and 
selective MRCK inhibitors discovered to date. Structure-guided medicinal chemistry 
facilitated compound optimization for potency and selectivity over closely related 
kinases including ROCK1 and ROCK2 (Figures 1 and 2, Supplemental Figure 1, and 
Supplemental Tables 1-4). Consistent with the previously characterized cell 
biological roles of these proteins, MRCK inhibition led to dose-dependent decreases 
in MLC2 phosphorylation, morphological changes, and reduced cell motility and 
invasion into 3D matrices at concentrations below cytotoxic levels (Figure 5). 
Inhibition of proliferation (e.g. Figures 4 and 6B) was observed at BDP9066 
concentrations higher than required for significant substrate phosphorylation, likely 
indicating a need for near complete inhibition of activity to provoke anti-proliferative 
responses. Furthermore, topical application of BDP9066 to mice undergoing a 
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DMBA/TPA chemical carcinogenesis protocol resulted in the therapeutic effect of 
significantly reduced papilloma volumes associated with micromolar compound 
levels in skin and reduced MRCKα S1003 autophosphorylation (Figure 7). The 
discovery of these compounds will enable further exploration of MRCK functions and 
roles in cancer, which will be important for determining how MRCK inhibition would 
be clinically applicable. 
 The Rho GTPase family effectors ROCK1, ROCK2, MRCKα and MRKCβ 
phosphorylate common substrates including MLC2, the myosin-binding subunit 
(MYPT1) of the MLC2 phosphatase complex, and the LIM kinases 1 and 2 (6,7,48). 
However, the ROCK and MRCK kinases appear to operate in different subcellular 
locales, with ROCK actions being more dispersed and MRCK acting primarily close 
to the plasma membrane. These differing sites of action likely explain why the 
combined inhibition of ROCK and MRCK together is more effective at blocking tumor 
cell invasion (15,16). It has been proposed that compounds that inhibit both ROCK 
and MRCK kinases would be more effective as anti-metastatic therapeutics than 
agents that were selective for one or the other (20). This hypothesis may be correct, 
but less selective inhibitors would not be useful as chemical biology tools to explore 
kinase-specific biological roles. In addition, in situations where only inhibition of 
MRCK was necessary for therapeutic effect, the additional ROCK inhibitory actions 
might lead to undesirable responses, such as dose-limiting hypotension. The highly 
potent and selective inhibitors BDP8900 and BDP9066 will enable studies focused 
on discovery of MRCK actions and roles in cancer. 
 Compounds that block tumor cell invasion are likely to be beneficial through a 
combination of effects, including reduced primary tumor growth and local invasion, 
as well as decreased dissemination and metastasis. For example, there were 
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multiple beneficial effects on pancreatic tumor growth and spread when mice were 
treated with ROCK inhibitors, including sensitization of tumors to standard of care 
therapeutics (49,50). Given that compounds which target processes that contribute 
to tumor cell invasion do not directly lead to cytotoxicity, they are unlikely to induce 
easily monitored responses such as tumor shrinkage in patients with advanced 
cancers, making the clinical development process more challenging than for 
“classical” cytotoxic type chemotherapeutics. Instead, clinical benefit from anti-
invasive drug administration would more likely be observed in alternative scenarios, 
such as long-term adjuvant treatment as part of post-therapy management, or in 
situations where local tissue invasion rather than distant metastasis is the cause of 
morbidity and mortality, as is the case for invasive gliobastoma (51). Additional pre-
clinical studies will help to define the contexts in which anti-invasive compounds, 
such as the MRCK inhibitors BDP8900 and 9066, are most likely to be beneficial for 
cancer patient therapy. 
 Indications consistent with a role of MRCKα or MRCKβ in cancer include 
elevated expression and gene copy number variations. A “poor prognosis gene” 
expression signature, associated with increased incidence of distant metastasis in 
fewer than 5 years, included MRCKβ (indicated as PK428) (52), while the MRCKα 
gene was found to be amplified in 491/2051 (24%) of breast cancer samples (53). 
However, an additional possibility is that increased MRCK activity is a common 
mechanism contributing to cancer, which would not necessarily be associated with 
changes in MRCK expression. Increased MRCK activity might be trigged from 
upstream signals via CDC42, which could be activated through elevated expression, 
loss of inhibitory GTPase-activating proteins (GAPs), increased expression or 
activating mutation of guanine-nucleotide exchange factors (GEFs), or aberrant 
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activity of regulators further upstream, such as receptor tyrosine kinases (54). 
Furthermore, mechanical stimulation of CDC42 by the extracellular 
microenvironment (55) may be another pathway leading to MRCK activation. A direct 
way to assess MRCK activation state is through the identification of 
autophosphorylation sites that report on activity status. A total of 8 phosphorylation 
sites were identified in wild-type MRCKα, but not the kinase dead K106M mutant, 
consistent with their being autophosphorylation events (Figure 5, Supplemental 
Tables 7 and 8). A phospho-sensitive pS1003 confirmed that phosphorylation of this 
site was mediated by an intramolecular mechanism, and was dependent on MRCK 
activity, supporting the conclusion that S1003 was autophosphorylated (Figure 5). 
Furthermore, the antibody reagent could be used in formalin-fixed paraffin 
embedded mouse tissue samples to interrogate MRCKα activity in tumors, or 
following BDP9066 treatment (Figures 5 and 7). Similarly, ROCK1 S1333 
phosphorylation (41) and ROCK2 S1366 phosphorylation (42) were shown to be 
associated with kinase activity, and that phosphorylation-state sensitive antibodies 
could be used to assess ROCK activity in clinical cancer samples (43). Therefore, 
MRCKα and MRCKβ phospho-selective antibodies raised against 
autophosphorylation sites are likely to be very useful tools to identify cancer types 
that would benefit from MRCK inhibitor treatment. Although MRCKα S1003 
autophosphorylation was validated and the phospho-sensitive antibody revealed 
increased staining in mouse skin tumors (Figure 5), other sites that have been 
identified in broad-scale phosphoproteomics studies might be better candidates for 
further evaluation, such as the putative autophosphorylation site S1629. 
 A role for MRCK in squamous cell carcinoma was previously indicated by 
microarray expression analysis of normal human skin versus epidermal SCC (Figure 
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5K) (44) and by a GM mouse model of epidermal SCC induced by oncogenic Hras 
expression combined with Notch1 inhibition (46). Using validated antibodies for 
MRCKα, phosphorylated MRCKα S1003 and MRCKβ, there was increased staining 
of each in two GM skin cancer models, and especially increased staining in the 
DMBA/TPA chemical carcinogenesis model (Figure 5L). Furthermore, BDP9066 
topical application significantly decreased phosphorylated MRCKα S1003 staining 
and tumor volumes (Figure 7), consistent with antibody staining for MRCK 
autophosphorylation being both an indicator of an association between MRCK 
activity with cancer, and a predictor of therapeutic response to inhibitor treatment. 
The approach described, in which differences between the phosphorylation of wild-
type versus kinase-dead versions were used to identify autophosphorylation events 
that could be used to monitor activation states, has the potential to be applied to 
additional kinases to evaluate the associations between activity and cancer, and to 
predict therapeutic responses. Monitoring kinase activity by immunohistochemical 
approaches would be a complementary or alternative approach that could be applied 
to signaling pathways in which activating mutations are not major factors. 
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Figure Legends 
Figure 1. Inhibition of MRCK activity in vitro and in cells by BDP8900 and 
BDP9066. (A) Structures of 7-azaindole-3-carbonitrile hit fragment, BD8900 and 
BDP9066. (B) BDP8900 dose-response curves for inhibition of MRCKα, MRCKβ, 
ROCK1 and ROCK2 kinase activity in vitro at 1 µM ATP. (C) BDP9066 dose-
response curves for inhibition of MRCKα, MRCKβ, ROCK1 and ROCK2 kinase 
activity in vitro at 1 µM ATP. Results shown are mean + SD of duplicate independent 
replicates. (D) Cells expressing doxycycline-induced MRCKβ, ROCK1 or ROCK2 
kinase domains were treated with BDP8900 at indicated concentrations for 60 
minutes prior to lysis and quantitative western blotting. Inhibition of MLC2 
phosphorylation by BDP8900 for each induced kinase domain. Results shown are 
mean + SEM of 3-4 independent replicates. (E) Cells expressing doxycycline-
induced MRCKβ, ROCK1 or ROCK2 kinase domains were treated with BDP9066 at 
indicated concentrations for 60 minutes prior to lysis and quantitative western 
blotting. Inhibition of MLC2 phosphorylation by BDP8900 for each induced kinase 
domain. Results shown are mean + SEM of 3-4 independent replicates. 
 
Figure 2. Detailed selectivity profiles for BDP8900 and BDP9066. 
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(A) Percentage kinase inhibition by 1 µM BDP8900 and BDP9066 were ranked and 
displayed by heat map. (B) Plot of inhibition by BDP8900 and BDP9066, kinases 
selected for detailed dose-response analysis indicated with red dot. ROCK1 was 
selected to additionally represent ROCK2 (black dot). Dotted line represents Deming 
regression (slope deviation from zero, p<0.0001). (C) BDP8900 dose-response 
curves for inhibition of indicated kinases in vitro. Results shown are mean + SD of 
duplicate independent replicates. (D) BDP9066 dose-response curves for inhibition 
of indicated kinases in vitro. Results shown are mean + SD of duplicate independent 
replicates. (E) BDP8900 and BDP9066 dose-response curves for competitive 
inhibition of tracer binding to DMPK in vitro, with calculated Kd values. Results shown 
are mean + SD of duplicate independent replicates. (F) Natural log Ki or Kd (nM) 
values of BDP8099 and BDP9066 determined using in-house optimized assay 
conditions (red dots), by outsourced assays (black dots) or competition binding 
assay (purple dot). Dashed line represents Deming regression (slope deviation from 
zero, p<0.0001). 
 
Figure 3. Structure of MRCKβ in complex with BDP8900 and BDP9066. 
(A) BDP8900 or (B) BDP9066 bound to the MRCKβ ATP-binding site in stereo 
views. Protein residues (grey) are labelled with the single-letter amino acid code and 
residue number, selected water molecules are indicated by red spheres. Ligands are 
shown in purple with σA-weighted |Fo|-|Fc|,ϕc electron density maps calculated prior 
to the initial inclusion of the ligand in refinement contoured at 3.0σ (dark blue). 
Potential hydrogen bonds are highlighted by dotted black lines. (C) Detailed view of 
the BDP9066 spiro moiety. The ligand is shown in cyan with a semitransparent 
surface. (D) Comparison of the binding modes of BDP9066 (cyan) and BDP5290 
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(blue, PDB ID 4UAL). Protein residues, pocket waters and potential hydrogen bonds 
are shown as before and colored to match the ligand.  
 
Figure 4. Evaluation of cancer cell line sensitivities to MRCK inhibitors. 
(A) Cancer cell lines (n = 757), divided into 45 cancer types, were treated with 7 
concentrations of a half-log dilution series of BDP8900 (top concentration = 10 μM). 
After 72 hours, cell density was measured, EC50 values calculated and MANOVA 
performed to identify cancer types significantly (p<0.05) sensitive (green triangles) or 
resistant (red triangles) to BDP8900 relative to all cancers (blue triangles) 
considered together. Purple lines indicate mean EC50 for each cancer type. (B) 
Sensitivity or resistance to BDP9066 was determined as described above. Cancer 
types significantly (p<0.05) sensitive (red triangles) or resistant (red triangles) from 
all cancers (blue triangles) are indicated. (Abbreviations: NSCLC, Non-small cell lung 
cancer; SCC, Squamous cell carcinoma). (C) Mean EC50 values for each cancer 
type to BDP8900 and BDP9066 were plotted, dark green dots indicate cancer types 
significantly sensitive to both inhibitors, light green dots indicate significant sensitivity 
to one inhibitor, dark red dots indicate significant resistance to both inhibitors, pink 
dots indicate significant resistance to one inhibitor (all p<0.05), relative to all cancers 
(bleu dot). Deming regression indicates that the there is a significant (p<0.0001) 
relationship between the responses of cancer types to both drugs. (Abbreviations for 
sensitive cancer types: AML, Acute myeloid leukemia; CML, Chronic myeloid 
leukemia; HNO, Hematopoietic neoplasm other; LLeu, Lymphoblastic leukemia; 
LNO, Lymphoid neoplasm other). 
 
Figure 5. MRCKα S1003 autophosphorylation as a biomarker of activity. 
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(A) Stained SDS-PAGE gel (left) of FLAG immunoprecipitated FLAG-MRCKα and 
FLAG-MRCKα K106M after in vitro 32P incorporation assay. Arrow indicates MRCKα. 
Gel autoradiograph (right) shows 32P labelling of MRCKα. MW = molecular weight. 
(B). Stained SDS-PAGE gel (left) of FLAG-immunoprecipitates from control HEK293 
cells, or cells transfected with pEF-FLAG-MRCKα or pEF-FLAG-MRCKα K106M. 
Arrow indicates MRCKα. MW = molecular weight. Higher energy collision 
dissociation (HCD) MS/MS fragmentation spectra (right) of MRCKα tryptic peptide 
999-1009 containing S1003 (red lettering) in MRCKα or MRCKα K106M 
(phosphorylation inferred from y7, y7-H3PO4 and y6 signals indicated with green 
arrows). See Supplemental Table 8 for theoretical y and b fragmentation ion series 
masses. Diagram of MRCKα protein domains (inset) illustrating location of S1003. 
(KD = kinase domain, CC = Coiled-coiled domain, C1 = C1 diacylglycerol binding 
domain, PH = Pleckstrin homology domain, CH = Citron Homology domain, CRIB = 
Cdc42/Rac interactive binding motif). (C). Dot blot of MRCKα peptides (10 to 500 pg) 
containing phosphorylated S1003 (peptide P) or unphosphorylated S1003 (peptide 
U), stained with pS1003 antibody (D). Western blots of FLAG-immunoprecipitated 
FLAG-MRCKα stained with untreated pS1003 antibody, or pS1003 antibody pre-
incubated with phosphorylated S1003 peptide P or unphosphorylated peptide U (E). 
Western blots of FLAG-immunoprecipitated FLAG-MRCKα, incubated in 
phosphatase buffer without (control) or with lambda phosphatase (phosphatase) (F). 
Western blot of FLAG-immunoprecipitated FLAG-MRCKα, FLAG-MRCKα K106M or 
FLAG-MRCKα S1003A. (G). Western blot (left) of FLAG-immunoprecipitated FLAG-
MRCKα incubated in kinase buffer in the absence or presence of recombinant 
CDC42 Q61L protein. Relative S1003 phosphorylation revealed that CDC42 
significantly increased autophosphorylation. Results shown are means ± SEM from 3 
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experiments. Student’s t-test (*** = p<0.001).  (H). Western blots of HEK293 cells 
expressing FLAG-MRCKα treated with DMSO, 3 µM BDP5290 or 1 µM BDP9066 (I). 
Western blots of FLAG immunoprecipitated FLAG-MRCKα∆C or FLAG-MRCKα 
K106M untreated or treated with lambda phosphatase, or treated with lambda 
phosphatase and then incubated in kinase buffer to allow autophosphorylation 
(AutoPhos). (J) Western blots of FLAG-immunoprecipitated FLAG-MRCKα, 
untreated or treated with lambda phosphatase (upper panel). Incubation with kinase 
buffer resulted in autophosphorylation (pS1003; lower left panel) and recombinant 
MLC2 substrate phosphorylation (pMLC2; lower right panel) (K). Western blots of 
FLAG-immunoprecipitated FLAG-MRCKα, FLAG-MRCKα K106M or FLAG-MRCKα 
S1003A incubated in vitro with recombinant MLC2 in a kinase buffer (left). Relative 
MLC2 phosphorylation by each kinase revealed that K106M significantly reduced 
activity, while S1003A was not different from wild-type. Results shown are means ± 
SEM from 5 independent experiments. One way Kruskal-Wallis ANOVA followed by 
post-hoc Dunn’s multiple comparison (* = p<0.05). (L) Relative MRCKα (upper) and 
MRCKβ (lower) expression was significantly higher in cutaneous SCC relative to 
normal human skin determined by microarray analysis (45). Results shown are 
means ± SD from 6 normal skin and 5 SCC patients. Two-tailed Mann-Whitney test 
of significance (** = p<0.01). (M) Immunohistochemistry of MRCKα, MRCKα pS1003 
or MRCKβ in benign papillomas from mice expressing oncogenic Hras in epidermal 
keratinocytes, or in well-differentiated squamous cell carcinomas resulting from 
Hras/c-Fos/Pten-/- genetic modifications or DMBA/TPA chemical carcinogenesis. 
Scale bars = 100 µm. 
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Figure 6. BDP9066 affects MLC2 phosphorylation, morphology, migration and 
invasion of human SCC12 squamous cell carcinoma. (A) Western blots (left) 
showing dose dependent inhibition (right) of MLC2 phosphorylation by BDP9066 in 
SCC12 cells. Results shown are means ± SEM from 3 independent replicates. (B). 
SCC12 viability as a function of BDP9066 concentration after 24 hours treatment. 
Results shown are means ± SEM from 3 independent replicates. (C). High content 
analysis of SCC12 morphology following treatment with DMSO vehicle or 0.5 µM 
BDP9066 for 2 hours. Multiparametric analysis was used to define regular (green), 
elongated (red) and irregular (blue) SCC12 cell morphologies. Scale bar represents 
100 µm. (D) Percentages of each SCC12 cell shape as functions of BDP9066 
concentration after 2 hours treatment. Results shown are means ± SEM from 3 
independent replicates. (E) Individual SCC12 cell morphology parameters (cell 
length, cell width, width/length ratio, cell area, cell roundness) as functions of 
BDP9066 concentration after 2 hours treatment. Results shown are means ± SEM 
from 3 independent replicates. (F). Representative images of phalloidin-stained 
filamentous actin structures in SCC12 cells treated with DMSO or 1 μM BDP9066 for 
~18 hours. Scale bar = 10 µm. (G). Tracks of SCC12 cell migration (120 cells) 
treated with DMSO (left) or 0.4 μM BDP9066 (right) over 6 hours. Each line 
represents the path of a single cell from the origin, with final position indicated by a 
dot. (H). Accumulated distance, Euclidean distance, velocity and directionality of 
SCC12 cells treated with DMSO or 0.4 μM BDP9066 for each tracked cell over 6 
hours. Results shown are means ± SEM from 120 individual cells. Two tailed 
unpaired t-tests were used to determine significance (* = p<0.05, *** = p<0.001). (I). 
Representative images of organotypic invasion by SCC12 cells cultured with medium 
supplemented with DMSO (left) or 0.4 μM BDP9066 (right). Scale bars represent 100 
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µm. (J). Percentage of invading SCC12 cells in organotypic invasion assays 
following treatment with DMSO or 0.4 μM BDP9066. Results shown are means ± 
SEM from 6 independent replicates. Two-tailed Mann-Whitney test of significance (** 
= p<0.01). 
 
Figure 7. In vivo application of BDP9066 in a DMBA/TPA mouse model of SCC. 
(A) Topical application of 4 X 25 µg BDP9066 over 2 days to dorsal skin led to 
measurable drug levels in the skin that were significantly higher than in blood. 
Results shown are means ± SD from 5 independent mice, each indicated by a data 
point. Two-tailed Mann-Whitney test of significance (** = p<0.01). (B) Representative 
MRCKα pS1003 immunohistochemical staining of mouse skin sections (left) topically 
treated with DMSO or 4 X 25 µg BDP9066 over 2 days. Scale bars represent 100 
µm. Topical administration of BDP9066 (red dots) led to significant reduction in 
positive epidermal staining for MRCKα pS1003 (right). Results shown are means ± 
SD from 5 independent mice per condition, each indicated by a data point. Two-
tailed Mann-Whitney test of significance (* = p<0.05). (C). Skin (left) or blood (right) 
BDP9066 concentrations following topical administration of a single 10 µg dose or 4 
X 25 µg doses of BDP9066 over 2 days. Results shown are means ± SD from 3 
independent mice per condition, each indicated by a data point. (D) Skin (left) or 
blood (right) BDP9066 concentrations following topical administration of a single 25 
µg dose (pink dots) or 8 X 25 µg doses of BDP9066 (red dots; 4 days on, 2 days off, 
4 days on) at indicated times after final administration. Results shown are means ± 
SD from 3 independent mice per condition, each indicated by a data point. (E) 
Timeline of DMBA (green arrow), TPA (purple arrow), DMSO (black arrow) or 
BDP9066 (red arrow) administration, with each day represented by a rectangle. (F) 
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Representative images of cagemate DMBA/TPA treated mice with topical application 
of DMSO or BDP9066 as indicated. (G) Total endpoint papilloma numbers per 
mouse. Results shown are means ± SD from 20 independent mice per condition, 
each indicated by a data point. (H) Total tumor volume (left) and average papilloma 
volume (right) per mouse. Results shown are means ± SD from 20 independent mice 
per condition, each indicated by a data point. Two tailed unpaired t-tests were used 
to determine significance (* = p<0.05). (I) Blood and skin BDP9066 concentrations at 
endpoint. Results shown are means ± SD from 3 independent mice for blood and 10 
mice for skin, each indicated by a data point. Two-tailed Mann-Whitney test of 
significance (** = p<0.001). (J) Representative MRCKα pS1003 staining of 
DMBA/TPA skin sections treated topically with DMSO or BDP9066. Scale bars 
represent 100 µm. (K). Cytoplasmic histoscores of MRCKα pS1003 staining of 
DMBA/TPA treated skin (left) or papilloma (right) sections that had been 
administered DMSO (black dots) or BDP9066 (red dots). Results shown are means 
± SD from 19 independent mice per condition, each indicated by a data point. Two 
tailed unpaired t-tests were used to determine significance (* = p<0.05). 
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